{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T09:25:49Z","timestamp":1789896349786,"version":"4.0.1"},"reference-count":51,"publisher":"National Academy of Sciences","issue":"41","content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2016,10,11]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis as well as Huntington\u2019s disease. It is thought that laquinimod has a primary effect on the peripheral innate immune system and also acts directly on resident cells within the CNS. However, the exact mechanism of action of laquinimod has not been fully elucidated. We investigated gene expression in laquinimod-treated mice and show induction of genes downstream to activation of the aryl hydrocarbon receptor (AhR). In this paper, we examine the role of the AhR in laquinimod treatment of experimental autoimmune encephalomyelitis and demonstrate that AhR is the molecular target of laquinimod in this model.<\/jats:p>","DOI":"10.1073\/pnas.1607843113","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T20:48:35Z","timestamp":1474922915000},"update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":137,"title":["Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor"],"prefix":"10.1073","volume":"113","author":[{"given":"Joel","family":"Kaye","sequence":"first","affiliation":[{"name":"Discovery &amp; Product Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Piryatinsky","sequence":"additional","affiliation":[{"name":"Discovery &amp; Product Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Birnberg","sequence":"additional","affiliation":[{"name":"Personalized &amp; Predictive Medicine, Analytics and Big Data, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Hingaly","sequence":"additional","affiliation":[{"name":"Discovery &amp; Product Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raymond","sequence":"additional","affiliation":[{"name":"Discovery &amp; Product Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Kashi","sequence":"additional","affiliation":[{"name":"Discovery &amp; Product Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat","family":"Amit-Romach","sequence":"additional","affiliation":[{"name":"Discovery &amp; Product Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio S.","family":"Caballero","sequence":"additional","affiliation":[{"name":"Immuneering Corporation, Cambridge, MA 02412;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Towfic","sequence":"additional","affiliation":[{"name":"Immuneering Corporation, Cambridge, MA 02412;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Ator","sequence":"additional","affiliation":[{"name":"Discovery &amp; Product Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"Discovery &amp; Product Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphna","family":"Laifenfeld","sequence":"additional","affiliation":[{"name":"Personalized &amp; Predictive Medicine, Analytics and Big Data, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aric","family":"Orbach","sequence":"additional","affiliation":[{"name":"Discovery &amp; Product Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Shinar","sequence":"additional","affiliation":[{"name":"Discovery &amp; Product Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Marantz","sequence":"additional","affiliation":[{"name":"Discovery &amp; Product Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Grossman","sequence":"additional","affiliation":[{"name":"Personalized &amp; Predictive Medicine, Analytics and Big Data, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Knappertz","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[{"name":"Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Laufer","sequence":"additional","affiliation":[{"name":"Discovery &amp; Product Development, Global Research &amp; Development, Teva Pharmaceutical Industries Ltd., Netanya 42504, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","article-title":"Placebo-controlled trial of oral laquinimod for multiple sclerosis","volume":"366","author":"Comi G","year":"2012","unstructured":"G Comi, , Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med; ALLEGRO Study Group 366, 1000\u20131009 (2012).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/jnnp-2013-306132","article-title":"Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage","volume":"85","author":"Filippi M","year":"2014","unstructured":"M Filippi, , Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry; ALLEGRO Study Group 85, 851\u2013858 (2014).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00415-014-7264-4","article-title":"A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis","volume":"261","author":"Vollmer TL","year":"2014","unstructured":"TL Vollmer, , A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol; BRAVO Study Group 261, 773\u2013783 (2014).","journal-title":"J Neurol"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jneuroim.2010.07.009","article-title":"Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis","volume":"227","author":"Wegner C","year":"2010","unstructured":"C Wegner, , Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 227, 133\u2013143 (2010).","journal-title":"J Neuroimmunol"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2012.06.005","article-title":"Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis","volume":"251","author":"Aharoni R","year":"2012","unstructured":"R Aharoni, , Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 251, 14\u201324 (2012).","journal-title":"J Neuroimmunol"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ajpath.2012.05.011","article-title":"Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod","volume":"181","author":"Mishra MK","year":"2012","unstructured":"MK Mishra, J Wang, C Silva, M Mack, VW Yong, Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am J Pathol 181, 642\u2013651 (2012).","journal-title":"Am J Pathol"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"e33797","DOI":"10.1371\/journal.pone.0033797","article-title":"Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity","volume":"7","author":"Schulze-Topphoff U","year":"2012","unstructured":"U Schulze-Topphoff, , Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One 7, e33797 (2012).","journal-title":"PLoS One"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ajpath.2011.09.037","article-title":"Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor","volume":"180","author":"Th\u00f6ne J","year":"2012","unstructured":"J Th\u00f6ne, , Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 180, 267\u2013274 (2012).","journal-title":"Am J Pathol"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/brain\/awt023","article-title":"Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis","volume":"136","author":"Jolivel V","year":"2013","unstructured":"V Jolivel, , Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 136, 1048\u20131066 (2013).","journal-title":"Brain"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1177\/1352458512469698","article-title":"Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis","volume":"19","author":"Ruffini F","year":"2013","unstructured":"F Ruffini, , Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult Scler 19, 1084\u20131094 (2013).","journal-title":"Mult Scler"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/brb3.174","article-title":"Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis","volume":"3","author":"Moore S","year":"2013","unstructured":"S Moore, , Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis. Brain Behav 3, 664\u2013682 (2013).","journal-title":"Brain Behav"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/acn3.67","article-title":"Laquinimod reduces neuroaxonal injury through inhibiting microglial activation","volume":"1","author":"Mishra MK","year":"2014","unstructured":"MK Mishra, , Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Ann Clin Transl Neurol 1, 409\u2013422 (2014).","journal-title":"Ann Clin Transl Neurol"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0028-3908(02)00015-1","article-title":"Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1\/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue","volume":"42","author":"Zou LP","year":"2002","unstructured":"LP Zou, , Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1\/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 42, 731\u2013739 (2002).","journal-title":"Neuropharmacology"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jneuroim.2014.06.012","article-title":"Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis","volume":"274","author":"Pitarokoili K","year":"2014","unstructured":"K Pitarokoili, , Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis. J Neuroimmunol 274, 38\u201345 (2014).","journal-title":"J Neuroimmunol"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/art.38259","article-title":"Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells","volume":"66","author":"Louren\u00e7o EV","year":"2014","unstructured":"EV Louren\u00e7o, M Wong, BH Hahn, MF Palma-Diaz, BJ Skaggs, Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells. Arthritis Rheumatol 66, 674\u2013685 (2014).","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.intimp.2015.10.019","article-title":"Laquinimod ameliorates spontaneous colitis in interleukin-10-gene-deficient mice with improved barrier function","volume":"29","author":"Sun J","year":"2015","unstructured":"J Sun, , Laquinimod ameliorates spontaneous colitis in interleukin-10-gene-deficient mice with improved barrier function. Int Immunopharmacol 29, 423\u2013432 (2015).","journal-title":"Int Immunopharmacol"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2014.04.002","article-title":"Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis","volume":"262","author":"Varrin-Doyer M","year":"2014","unstructured":"M Varrin-Doyer, SS Zamvil, U Schulze-Topphoff, Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol 262, 66\u201371 (2014).","journal-title":"Exp Neurol"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1124\/mol.106.032748","article-title":"Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: Results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro","volume":"71","author":"Hu W","year":"2007","unstructured":"W Hu, C Sorrentino, MS Denison, K Kolaja, MR Fielden, Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: Results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol 71, 1475\u20131486 (2007).","journal-title":"Mol Pharmacol"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"7939","DOI":"10.3390\/ijms15057939","article-title":"Aryl hydrocarbon receptor repressor and TiPARP (ARTD14) use similar, but also distinct mechanisms to repress aryl hydrocarbon receptor signaling","volume":"15","author":"MacPherson L","year":"2014","unstructured":"L MacPherson, , Aryl hydrocarbon receptor repressor and TiPARP (ARTD14) use similar, but also distinct mechanisms to repress aryl hydrocarbon receptor signaling. Int J Mol Sci 15, 7939\u20137957 (2014).","journal-title":"Int J Mol Sci"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.taap.2010.12.010","article-title":"Hepatic transcriptomic responses to TCDD in dioxin-sensitive and dioxin-resistant rats during the onset of toxicity","volume":"251","author":"Boutros PC","year":"2011","unstructured":"PC Boutros, , Hepatic transcriptomic responses to TCDD in dioxin-sensitive and dioxin-resistant rats during the onset of toxicity. Toxicol Appl Pharmacol 251, 119\u2013129 (2011).","journal-title":"Toxicol Appl Pharmacol"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3389\/fimmu.2014.00521","article-title":"Immunological relevance of the coevolution of IDO1 and AHR","volume":"5","author":"Jaronen M","year":"2014","unstructured":"M Jaronen, FJ Quintana, Immunological relevance of the coevolution of IDO1 and AHR. Front Immunol 5, 521 (2014).","journal-title":"Front Immunol"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3389\/fimmu.2014.00551","article-title":"Aryl hydrocarbon receptor and kynurenine: Recent advances in autoimmune disease research","volume":"5","author":"Nguyen NT","year":"2014","unstructured":"NT Nguyen, , Aryl hydrocarbon receptor and kynurenine: Recent advances in autoimmune disease research. Front Immunol 5, 551 (2014).","journal-title":"Front Immunol"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1124\/mol.112.078873","article-title":"Xenobiotics and loss of cell adhesion drive distinct transcriptional outcomes by aryl hydrocarbon receptor signaling","volume":"82","author":"Hao N","year":"2012","unstructured":"N Hao, , Xenobiotics and loss of cell adhesion drive distinct transcriptional outcomes by aryl hydrocarbon receptor signaling. Mol Pharmacol 82, 1082\u20131093 (2012).","journal-title":"Mol Pharmacol"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"20768","DOI":"10.1073\/pnas.1009201107","article-title":"An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis","volume":"107","author":"Quintana FJ","year":"2010","unstructured":"FJ Quintana, , An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 107, 20768\u201320773 (2010).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature06880","article-title":"Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor","volume":"453","author":"Quintana FJ","year":"2008","unstructured":"FJ Quintana, , Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453, 65\u201371 (2008).","journal-title":"Nature"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"9721","DOI":"10.1073\/pnas.0804231105","article-title":"Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells","volume":"105","author":"Kimura A","year":"2008","unstructured":"A Kimura, T Naka, K Nohara, Y Fujii-Kuriyama, T Kishimoto, Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 105, 9721\u20139726 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"e79819","DOI":"10.1371\/journal.pone.0079819","article-title":"Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo","volume":"8","author":"Duarte JH","year":"2013","unstructured":"JH Duarte, P Di Meglio, K Hirota, H Ahlfors, B Stockinger, Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo. PLoS One 8, e79819 (2013).","journal-title":"PLoS One"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"e106955","DOI":"10.1371\/journal.pone.0106955","article-title":"The aryl hydrocarbon receptor: Differential contribution to T helper 17 and T cytotoxic 17 cell development","volume":"9","author":"Hayes MD","year":"2014","unstructured":"MD Hayes, V Ovcinnikovs, AG Smith, I Kimber, RJ Dearman, The aryl hydrocarbon receptor: Differential contribution to T helper 17 and T cytotoxic 17 cell development. PLoS One 9, e106955 (2014).","journal-title":"PLoS One"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00281-013-0397-1","article-title":"Regulation of central nervous system autoimmunity by the aryl hydrocarbon receptor","volume":"35","author":"Quintana FJ","year":"2013","unstructured":"FJ Quintana, Regulation of central nervous system autoimmunity by the aryl hydrocarbon receptor. Semin Immunopathol 35, 627\u2013635 (2013).","journal-title":"Semin Immunopathol"},{"key":"e_1_3_4_30_2","first-page":"w13592","article-title":"Aryl hydrocarbon receptor controls regulatory CD4+ T cell function","volume":"142","author":"Pot C","year":"2012","unstructured":"C Pot, Aryl hydrocarbon receptor controls regulatory CD4+ T cell function. Swiss Med Wkly 142, w13592 (2012).","journal-title":"Swiss Med Wkly"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/ni.1912","article-title":"The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27","volume":"11","author":"Apetoh L","year":"2010","unstructured":"L Apetoh, , The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 11, 854\u2013861 (2010).","journal-title":"Nat Immunol"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ni.1915","article-title":"Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells","volume":"11","author":"Gandhi R","year":"2010","unstructured":"R Gandhi, , Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 11, 846\u2013853 (2010).","journal-title":"Nat Immunol"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"e23618","DOI":"10.1371\/journal.pone.0023618","article-title":"In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling","volume":"6","author":"Wu HY","year":"2011","unstructured":"HY Wu, , In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling. PLoS One 6, e23618 (2011).","journal-title":"PLoS One"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nm.3868","article-title":"Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-\u03b1","volume":"21","author":"Mascanfroni ID","year":"2015","unstructured":"ID Mascanfroni, , Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-\u03b1. Nat Med 21, 638\u2013646 (2015).","journal-title":"Nat Med"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/toxsci\/kfr218","article-title":"Exactly the same but different: Promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor","volume":"124","author":"Denison MS","year":"2011","unstructured":"MS Denison, AA Soshilov, G He, DE DeGroot, B Zhao, Exactly the same but different: Promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol Sci 124, 1\u201322 (2011).","journal-title":"Toxicol Sci"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00401-012-1009-1","article-title":"Reduced astrocytic NF-\u03baB activation by laquinimod protects from cuprizone-induced demyelination","volume":"124","author":"Br\u00fcck W","year":"2012","unstructured":"W Br\u00fcck, , Reduced astrocytic NF-\u03baB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol 124, 411\u2013424 (2012).","journal-title":"Acta Neuropathol"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1124\/mol.62.3.722","article-title":"2,3,7,8-Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NF-kappaB\/Rel in dendritic cells: p50 homodimer activation is not affected","volume":"62","author":"Ruby CE","year":"2002","unstructured":"CE Ruby, M Leid, NI Kerkvliet, 2,3,7,8-Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NF-kappaB\/Rel in dendritic cells: p50 homodimer activation is not affected. Mol Pharmacol 62, 722\u2013728 (2002).","journal-title":"Mol Pharmacol"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1074\/jbc.M113.505578","article-title":"Cross-talk between aryl hydrocarbon receptor and the inflammatory response: A role for nuclear factor-\u03baB","volume":"289","author":"Vogel CF","year":"2014","unstructured":"CF Vogel, , Cross-talk between aryl hydrocarbon receptor and the inflammatory response: A role for nuclear factor-\u03baB. J Biol Chem 289, 1866\u20131875 (2014).","journal-title":"J Biol Chem"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nm.4106","article-title":"Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor","volume":"22","author":"Rothhammer V","year":"2016","unstructured":"V Rothhammer, , Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med 22, 586\u2013597 (2016).","journal-title":"Nat Med"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/pr.114.009001","article-title":"The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology","volume":"67","author":"Esser C","year":"2015","unstructured":"C Esser, A Rannug, The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacol Rev 67, 259\u2013279 (2015).","journal-title":"Pharmacol Rev"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/intimm\/dxt011","article-title":"The roles of aryl hydrocarbon receptor in immune responses","volume":"25","author":"Nguyen NT","year":"2013","unstructured":"NT Nguyen, H Hanieh, T Nakahama, T Kishimoto, The roles of aryl hydrocarbon receptor in immune responses. Int Immunol 25, 335\u2013343 (2013).","journal-title":"Int Immunol"},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1124\/pr.113.007823","article-title":"Aryl hydrocarbon receptor control of adaptive immunity","volume":"65","author":"Quintana FJ","year":"2013","unstructured":"FJ Quintana, DH Sherr, Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol Rev 65, 1148\u20131161 (2013).","journal-title":"Pharmacol Rev"},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.smim.2015.10.002","article-title":"Aryl hydrocarbon receptor: Linking environment to immunity","volume":"27","author":"Cella M","year":"2015","unstructured":"M Cella, M Colonna, Aryl hydrocarbon receptor: Linking environment to immunity. Semin Immunol 27, 310\u2013314 (2015).","journal-title":"Semin Immunol"},{"key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.it.2015.11.007","article-title":"AHR function in lymphocytes: Emerging concepts","volume":"37","author":"Zhou L","year":"2016","unstructured":"L Zhou, AHR function in lymphocytes: Emerging concepts. Trends Immunol 37, 17\u201331 (2016).","journal-title":"Trends Immunol"},{"key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/eji.201445144","article-title":"Ultraviolet light converts propranolol, a nonselective \u03b2-blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand","volume":"45","author":"Dorgham K","year":"2015","unstructured":"K Dorgham, , Ultraviolet light converts propranolol, a nonselective \u03b2-blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand. Eur J Immunol 45, 3174\u20133187 (2015).","journal-title":"Eur J Immunol"},{"key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nm.4102","article-title":"CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands","volume":"22","author":"Lamas B","year":"2016","unstructured":"B Lamas, , CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med 22, 598\u2013605 (2016).","journal-title":"Nat Med"},{"key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin A","year":"2013","unstructured":"A Dobin, , STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: An efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao Y","year":"2014","unstructured":"Y Liao, GK Smyth, W Shi, featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1101\/gr.135350.111","article-title":"GENCODE: The reference human genome annotation for The ENCODE Project","volume":"22","author":"Harrow J","year":"2012","unstructured":"J Harrow, , GENCODE: The reference human genome annotation for The ENCODE Project. Genome Res 22, 1760\u20131774 (2012).","journal-title":"Genome Res"},{"key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: Precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law CW","year":"2014","unstructured":"CW Law, Y Chen, W Shi, GK Smyth, voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 15, R29 (2014).","journal-title":"Genome Biol"},{"key":"e_1_3_4_51_2","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie ME","year":"2015","unstructured":"ME Ritchie, , limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47 (2015).","journal-title":"Nucleic Acids Res"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1607843113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T10:56:14Z","timestamp":1654599374000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1607843113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":51,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2016,10,11]]}},"alternative-id":["10.1073\/pnas.1607843113"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1607843113","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,26]]},"assertion":[{"value":"2016-09-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}